A5039236556- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Healthcare Systems and Practices
- Health, Medicine and Society
- Bone health and treatments
- Chemotherapy-related skin toxicity
- Cancer survivorship and care
- Multiple and Secondary Primary Cancers
- Palliative Care and End-of-Life Issues
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Patient-Provider Communication in Healthcare
- Brain Metastases and Treatment
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Pain Management and Opioid Use
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Management of metastatic bone disease
- Advanced Breast Cancer Therapies
- Cancer Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Adrenal and Paraganglionic Tumors
- Blood groups and transfusion
Hôpital du Valais
2016-2025
HES-SO Valais-Wallis
2010-2024
National Cancer Registration Service
2021
University of Zurich
2021
Kantonsspital Graubünden
2021
Hôpital de Sion
2000-2020
Ospedale Civile Di Ivrea
2020
University Hospital of Lausanne
2012-2017
Clinica Luganese Moncucco
2017
Cal Humanities
2015
The present study assesses the choice of surgical procedure, oncologic results and quality life (QOL) outcomes in a retrospective cohort 53 patients with low-lying rectal cancers (within 6 cm anal verge) treated surgically following preoperative radiotherapy (RT, median dose 45Gy) or without concomitant 5-fluorouracil. QOL was assessed 23 by using two questionnaires developed Study Group European Organization for Research Treatment Cancer: EORTC QLQ-C30 QLQ-CR38. After interval 29 days from...
163 Background: While reducing skeletal-related events in patients (pts) with bone metastases (BM), protecting agents such as DN have adverse events. One major event is osteonecrosis of the jaw (ONJ), which can significantly impact quality life. The risk ONJ increases treatment duration and reaches cumulative rates up to 9%. We report a randomized phase III non-inferiority trial investigating optimal dose schedule denosumab (DN). Methods: Pts BM from mCRPC were 1:1 receive every 4 weeks...
Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared paclitaxel/bevacizumab. This multicenter, randomized phase III trial either paclitaxel (arm A) or daily oral capecitabine-cyclophosphamide B) as first-line treatment patients HER2-negative advanced cancer. The primary endpoint was the incidence of selected grade 3–5 adverse...
3503 Background: Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer patients. We assessed whether no continuation non-inferior to of after stop chemotherapy. Methods: In an open-label, phase 3 multicenter study conducted Switzerland, patients with unresectable having non-progressive disease 4-6 months chemotherapy were randomly assigned 1:1 ratio continuing (7.5 mg/kg every weeks) or treatment. CT scans done 6 weeks between...
Objectives The objectives were to describe patients' experiences of cancer care in Switzerland and explore the variation these by type cancer. Methods Swiss Cancer Patient Experiences (SCAPE) study was a cross-sectional, multicentre survey conducted 2018. Adult patients (n = 7145) with breast, prostate, lung, colorectal, skin or haematological from four large hospitals French-speaking invited complete survey. Logistic regressions used assess whether varied according type, adjusting for...
Abstract Background Patient experience surveys gather information on various aspects of care via numerous survey items. Identifying the most critical areas patient to prioritize for quality improvement can be challenging. The objective this study was determine which items are drivers influencing patients' overall rating cancer care. Methods Data from 2750 adult patients with second wave Swiss Cancer Experiences were analyzed. This cross‐sectional conducted in eight hospitals September 2021...
To assess the feasibility and efficacy of intensity-modulated radiation implemented with helical tomotherapy image-guided daily megavoltage computed tomography for head neck cancer.Between May 2010 2013, 72 patients were treated curative intent. The median age was 64 years, 57% undergoing definitive 43% postoperative radiotherapy. Primary tumour sites oral cavity (21%), oropharynx (26%), hypopharynx (20%), larynx (22%), others (11%). Staging included 4% stage I, 15% II, 26% III, 48% IVa, 7%...
Centralisation of cancer services is ongoing in many countries due to the rapid increase knowledge oncology, interdisciplinary treatments and economic pressure. This study investigated whether patients are willing accept this additional burden. All who came February 2012 for a consultation or an ambulant treatment were asked answer survey. The questionnaire covered among other six questions would be travel more frequently further away. These split two groups: one slightly efficacious therapy...
518 Background: Bevacizumab combined with chemotherapy has been shown to improve response rate and PFS in metastatic breast cancer. The aim of our study was demonstrate decreased toxicity metronomic chemotherapy/bevacizumab when compared paclitaxel/bevacizumab. Methods: In this multicenter, randomized phase III trial, we bevacizumab (10 mg/kg i.v. q 2 weeks) either paclitaxel (90 mg/m2) on days 1, 8, 15 a 4 week cycle (arm A) or daily oral capecitabine (3x500 mg) cyclophosphamide (50 B) as...
Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors, but knowledge their routine care use and therapeutic implications remains limited. This non-interventional study aimed to characterize real-world BTA patterns Switzerland.Non-interventional, cross-sectional involving oncologists across Switzerland who completed a Treating Physician questionnaire, providing data on clinical setting BTA-related practices, Patient Characteristics...
139 Background: DN given q4w has shown superiority in delaying skeletal related events over zoledronic acid (ZA). Recently it been demonstrated that ZA q12w is non-inferior to q4w. The objective of REDUSE show non-inferiority for versus terms SSE. Here we present an interim analysis the secondary endpoint HC. Methods: Patients (pts) with castration resistant prostate cancer (planned N=690) were randomized 1:1 (Arm A) vs B) after a 16 week induction phase application All pts received vitamin...
Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated quality life (QoL) and effectiveness this regimen daily clinical practice, according to RAS status, sex, prior targeted therapy, especially epidermal growth factor receptor inhibitors (EGFR-I). The primary endpoint was percentage whose EORTC QLQ-C30 global health status (GHS) improved or reduced by <5%...
The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination shown further improvement in clinical outcomes advanced and adjuvant patients. In low-grade ovarian tumors, inhibitor use also proposed. Here we present a patient with an excellent, lasting response to therapy alone. At first progression, after more than two years on monotherapy, could not identify any molecular mechanisms explaining resistance. After switch dual...
A 71-year-old man was treated for a left pleural epitheloid malignant mesothelioma in August 2005. The tumour found unresectable during thoracoscopy and staged as pT4N1M0 disease. Following...
The study aimed to investigate strategies prevent and treat cetuximab-induced skin reactions their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) recurrent/metastatic squamous cell of the head neck (SCCHN).This open-label, prospective observational was conducted Switzerland.A total 125 were included (n = 91 mCRC, n 34 SCCHN; mean age 63.3 years; 73.6% males). frequency acneiform rash grade ≥ 2 increased from 12.6% at week 21.7% 16. proportion who reported no...
A new subfield of oncology has emerged in the last twenty years to raise awareness and address specific needs elderly cancer patients, a population that was long neglected oncology. We sought understand individual experiences, as well moral social implications considering patients "treatable". Following an anthropological critical interpretative approach focusing on practical symbolic effects chemotherapy rapidly evolving medical field, we conducted 20 semi-structured interviews observations...
International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated patients with metastatic castration-sensitive prostate cancer (mCSPC) metastases. Whereas has never been studied in this patient population, shown to be ineffective decreasing the risk skeletal-related events. This study estimates prevalence and economic consequences of real-world use mCSPC Switzerland.To estimate frequency agent administration...
9059 Background: PPE, also known as hand-foot syndrome, is a distinctive adverse drug reaction of PLD treatment. has been detected in elevated concentrations eccrine sweat glands palms and soles. We postulated that prophylactic administration an antiperspirant (F511 cream) prior during treatment with could decrease the incidence PPE. Methods: Patients (pts) metastatic breast cancer treated monotherapy ≥10mg/m 2 per week applied to left or right hand foot corresponding placebo opposite site...